Solutions driven by innovative immunoproteomics technology
Innovative technology is at the core of Sengenics’ ability to identify and develop clinically relevant autoantibody biomarkers. Explore our proprietary technologies and learn how autoantibodies may hold the key to significant, new advances in precision medicine.
Explore Our Technology
Advance Your Understanding
Sengenics is a precision medicine company working to improve patient outcomes through physiologically relevant, data-guided decision making. Our solutions enable the discovery and validation of autoantibody biomarker signatures for patient stratification, therapeutic response prediction and development of companion diagnostics.
Copyright 2008 – 2022 Sengenics All rights reserved. Sengenics Corporation LLC. Registered in Delaware, USA no. 5739583 | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D
Design and development by RainCastle Communications.